596 related articles for article (PubMed ID: 26780907)
1. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
Yeang C; Cotter B; Tsimikas S
Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
[TBL] [Abstract][Full Text] [Related]
2. Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology.
Koschinsky ML; Boffa MB
Atherosclerosis; 2022 May; 349():92-100. PubMed ID: 35606081
[TBL] [Abstract][Full Text] [Related]
3. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.
Boffa MB; Koschinsky ML
Nat Rev Cardiol; 2019 May; 16(5):305-318. PubMed ID: 30675027
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.
Nsaibia MJ; Mahmut A; Boulanger MC; Arsenault BJ; Bouchareb R; Simard S; Witztum JL; Clavel MA; Pibarot P; Bossé Y; Tsimikas S; Mathieu P
J Intern Med; 2016 Nov; 280(5):509-517. PubMed ID: 27237700
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a) accelerates atherosclerosis in uremic mice.
Pedersen TX; McCormick SP; Tsimikas S; Bro S; Nielsen LB
J Lipid Res; 2010 Oct; 51(10):2967-75. PubMed ID: 20584868
[TBL] [Abstract][Full Text] [Related]
6. The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?
Boffa MB; Koschinsky ML
Curr Opin Lipidol; 2018 Jun; 29(3):259-267. PubMed ID: 29528858
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.
Boffa MB; Marcovina SM; Koschinsky ML
Clin Biochem; 2004 May; 37(5):333-43. PubMed ID: 15087247
[TBL] [Abstract][Full Text] [Related]
8. High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner.
Assini JM; Clark JR; Youssef A; Xing C; Doerfler AM; Park SH; Saxena L; Yaseen AB; Børen J; Gros R; Bao G; Lagor WR; Boffa MB; Koschinsky ML
Atherosclerosis; 2023 Nov; 384():117150. PubMed ID: 37290980
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) and calcific aortic valve stenosis: A systematic review.
Guddeti RR; Patil S; Ahmed A; Sharma A; Aboeata A; Lavie CJ; Alla VM
Prog Cardiovasc Dis; 2020; 63(4):496-502. PubMed ID: 32526213
[TBL] [Abstract][Full Text] [Related]
11. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers?
Koschinsky ML
Cardiovasc Hematol Disord Drug Targets; 2006 Dec; 6(4):267-78. PubMed ID: 17378772
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis.
Zheng KH; Tsimikas S; Pawade T; Kroon J; Jenkins WSA; Doris MK; White AC; Timmers NKLM; Hjortnaes J; Rogers MA; Aikawa E; Arsenault BJ; Witztum JL; Newby DE; Koschinsky ML; Fayad ZA; Stroes ESG; Boekholdt SM; Dweck MR
J Am Coll Cardiol; 2019 May; 73(17):2150-2162. PubMed ID: 31047003
[TBL] [Abstract][Full Text] [Related]
13. Transgenic rabbits expressing human apolipoprotein (a).
Fan J; Watanabe T
J Atheroscler Thromb; 2000; 7(1):8-13. PubMed ID: 11425047
[TBL] [Abstract][Full Text] [Related]
14. Pathobiology of Lp(a) in calcific aortic valve disease.
Mathieu P; Arsenault BJ; Boulanger MC; Bossé Y; Koschinsky ML
Expert Rev Cardiovasc Ther; 2017 Oct; 15(10):797-807. PubMed ID: 28816078
[TBL] [Abstract][Full Text] [Related]
15. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.
Capoulade R; Yeang C; Chan KL; Pibarot P; Tsimikas S
JAMA Cardiol; 2018 Dec; 3(12):1212-1217. PubMed ID: 30476957
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
Tsimikas S; Hall JL
J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
[TBL] [Abstract][Full Text] [Related]
17. [DIAGNOSIS AND TREATMENT OF ELEVATED LIPOPROTEIN(A) IN ISRAEL: CONSENSUS STATEMENT FROM THE ISRAEL SOCIETY FOR RESEARCH, PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND ISRAEL SOCIETY FOR CLINICAL LABORATORY SCIENCES].
Zafrir B; Durst R; Henig C; Henkin Y; Itzhakov E; Kaplan M; Gavish D
Harefuah; 2024 Mar; 163(3):185-190. PubMed ID: 38506362
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a): Expanding our knowledge of aortic valve narrowing.
Youssef A; Clark JR; Koschinsky ML; Boffa MB
Trends Cardiovasc Med; 2021 Jul; 31(5):305-311. PubMed ID: 32525013
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a): An underestimated inflammatory mastermind.
Dzobo KE; Kraaijenhof JM; Stroes ESG; Nurmohamed NS; Kroon J
Atherosclerosis; 2022 May; 349():101-109. PubMed ID: 35606070
[TBL] [Abstract][Full Text] [Related]
20. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.
Graham MJ; Viney N; Crooke RM; Tsimikas S
J Lipid Res; 2016 Mar; 57(3):340-51. PubMed ID: 26538546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
